Lofexidine (Lucemyra®, US Woldmeds LLC) is a medication historically used to treat high blood pressure which was approved by FDA as a first non-opioid drug for the mitigation of withdrawal symptoms to facilitate abrupt discontinuation of opioids in adults on May 16, 2018. Lucemyra is not a treatment for opioid use disorder (OUD), but can be used as part of a broader, long-term treatment plan for managing OUD.
Enamine has the world’s largest catalogue of building blocks which is monthly enriched with ca. 2,000 newly designed and synthesized compounds. Most of these compounds have been previously unknown and may already provide elegant solutions to your today’s challenges.
Being the global leader in supplying state-of-the-art chemical products for drug discovery (building blocks and screening compounds), Enamine also created a sophisticated ecommerce integration layer, allowing for a seamless eProcurment process to be enabled between buyers and vendors.
|Title:||REAL Compound Sales: Hit Exploration in REAL database
|Product range:||REAL Database
|Promotional period:||July 23, 2018 – December 31, 2018
|Prize:||Immediate 20% discount on purchase of the analogs requested through EnamineStore functionality “Hit Exploration in REAL database, 680 million compounds searched”
|Discount policy:||20% Discount applies only to the requests received from EnamineStore website. Please draw you hit molecule, search and select REAL analogue compounds. Upon sending your request using the corresponding button you will be granted with the said discount provided you confirm the order to our sales manager
Patient diversity and developing drug resistance can undermine the efficiency of existing therapies in a long-term pharmacological treatment of diseases, such as cancer and infections.
One of the promising strategies, in this case, is applying multicomponent therapeutics, leading the way to more personalized medicine. Approved drugs appear to be the ideal starting point for the development of novel multidrug treatments enjoying a fast track to new clinical applications.
Indeed, they are already known to be safe, effective and bioavailable. Last, but not least, they usually have well-defined targets and mechanisms of action.
Another important strategy in modern pharmaceutical research is drug repurposing. Drugs which once failed as effective treatments for one disease might well become “blockbuster” cures for another.
In order to extend e-commerce functionality and add new features to its websites, Enamine participated in 2017 ChemAxon User Meeting In Budapest to explore novel cheminformatics tools and discuss collaboration opportunities with ChemAxon. The event provided a solid platform for gathering specialists from both biopharma and research software industries and discussing new IT products, use cases and the future of new IT tools in the area of life sciences.